Related Experiment Video

Updated: Mar 17, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K

CDK4/6 inhibition in luminal breast cancer

Simon Peter Gampenrieder1, Gabriel Rinnerthaler1, Richard Greil1

  • 1IIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Müllner Hauptstraße 48, 5020 Salzburg, Austria ; Laboratory of Immunological and Molecular Cancer Research, Center for Clinical Cancer and Immunology Trials, Salzburg Cancer Research Institute, Salzburg, Austria ; Cancer Cluster Salzburg, Salzburg, Austria.

Memo
|July 19, 2016
PubMed

Insights

Endocrine therapy is standard for estrogen receptor-positive breast cancer. Combining it with palbociclib, a CDK4/6 inhibitor, shows promise for overcoming resistance in metastatic disease.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Estrogen receptor-positive breast cancer treatment relies on endocrine therapy.
  • Intrinsic and acquired resistance to endocrine therapy are significant challenges in metastatic breast cancer.
  • Combination strategies are crucial for overcoming endocrine resistance.

Approach:

  • Investigated the efficacy of palbociclib, a selective CDK4/6 inhibitor, in combination with endocrine therapy.
  • Evaluated palbociclib in both first-line and pretreated metastatic luminal breast cancer settings.
  • Assessed the safety profile of the combination therapy.

Key Points:

  • Palbociclib in combination with endocrine therapy demonstrated promising results in metastatic luminal breast cancer.
  • The drug combination is effective in both first-line and pretreated patient populations.
  • Palbociclib exhibits a manageable safety profile, with neutropenia being the most common side effect.

Conclusions:

  • Combination therapy with palbociclib and endocrine therapy represents a viable strategy to overcome endocrine resistance in metastatic breast cancer.
  • Palbociclib offers a new therapeutic option for patients with advanced ER+ breast cancer.
  • Regulatory approvals are anticipated in major markets, highlighting the clinical significance of this approach.
Keywords:
AbemaciclibCDK4/6 inhibitorsEndocrine resistancePalbociclibRibociclib

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K